Magnet Biomedicine

Magnet Biomedicine is a biotechnology company developing small-molecule molecular glues — compounds that induce or stabilize interactions between two proteins that do not normally interact. Its TrueGlue discovery platform pairs a disease target protein with a rationally selected "presenter" protein; when a TrueGlue binds the presenter, a neo protein-protein interface is created and a ternary complex forms, producing presenter-dependent engagement of the target. The platform combines screening technologies, proprietary chemical libraries, human genetics and proteomics data, and strategic selection of target/presenter pairs.

The company positions its work beyond the dominant molecular glue use case of targeted protein degradation via E3 ligases, instead exploring the broader protein landscape to enable additional mechanisms of action. Stated potential advantages include drugging targets with poor ligandability, using tissue-restricted presenters to limit on-target/off-tissue toxicity, and using extracellular presenters so that oral small molecules could substitute for injectable biologics against cytokines and receptors. At launch the company described a portfolio of programs spanning oncology, immune disorders, and cardiovascular disease, with CEO Brian Safina declining to disclose specific targets and noting an initial focus on clinically and genetically validated targets; later company materials emphasize cancer and immune disorders.

Magnet emerged from stealth in September 2023 with a $50 million Series A and has since built out a leadership team including a President & CEO, Chief Medical Officer, Chief Business Officer, SVP of Research, and vice presidents for drug discovery, operations, portfolio/program management, and clinical operations.

Founding story

Magnet was co-founded by a group of academic scientists: Stuart Schreiber (Broad Institute, Harvard University), a molecular glue researcher who in the early 1990s showed that cyclosporin acts as a molecular glue inducing protein-protein interactions; 2017 Nobel Laureate Michael Rosbash (Brandeis University); chemoproteomics researcher Benjamin Cravatt (The Scripps Research Institute); human geneticist Richa Saxena (Massachusetts General Hospital, Broad Institute); and chemical biologist David Spiegel (Yale University). According to CEO Brian Safina, the company builds on Schreiber's decades of molecular glue research, with Schreiber judging that advances in proteomics, high-throughput screening, and bioinformatics made the time right to expand molecular glue discovery beyond degradation. Newpath Partners was the founding and initial investor. One aggregator source states the company was founded in 2019, though this is not corroborated by other sources.

Business model

Magnet operates as a platform-based drug discovery company, generating internal preclinical programs from its TrueGlue platform while also licensing and co-developing programs with large pharmaceutical partners. Its Lilly agreement provides upfront and near-term payments, an equity investment, development/regulatory/commercial milestones, and tiered royalties on global net sales.

Disclosed revenue sources are partnership-based: the Eli Lilly collaboration provides up to $40 million in upfront and near-term payments plus an equity investment, eligibility for more than $1.25 billion in milestones, and tiered royalties on global net sales. No product revenue is described.

Traction

Magnet raised a $50 million Series A in September 2023, which the CEO said would fund platform build-out, lead optimization, candidate nomination, and IND preparation. In February 2025 it secured a collaboration and license agreement with Eli Lilly in oncology worth up to $40 million in upfront/near-term payments plus equity and more than $1.25 billion in potential milestones with tiered royalties. Its website lists roughly 30 scientific and operational staff plus leadership, and it continues to recruit.

Latest developments

Most recent disclosed developments are the appointment of Nick Vlahakis, M.B.B.S., as Chief Medical Officer (January 13, 2026) and Bharat Reddy, Ph.D., as Chief Business Officer (November 4, 2025), following the February 2025 Lilly collaboration and license agreement. In its January 2026 release the company describes itself as an induced-proximity biotech advancing rational molecular glue discovery.